ArticlemAbs2016

The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.

Gábor Tóth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.